blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3345905

EP3345905 - DEUTERATED BENZOQUINOLIZINE DERIVATIVES AS INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.07.2022
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  30.07.2021
FormerGrant of patent is intended
Status updated on  15.03.2021
FormerExamination is in progress
Status updated on  08.02.2021
FormerGrant of patent is intended
Status updated on  28.09.2020
FormerExamination is in progress
Status updated on  14.08.2020
FormerGrant of patent is intended
Status updated on  02.04.2020
FormerExamination is in progress
Status updated on  29.04.2019
FormerRequest for examination was made
Status updated on  25.01.2019
FormerThe application has been published
Status updated on  08.06.2018
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
Auspex Pharmaceuticals, Inc.
400 Interpace Parkway
Parsippany NJ 07054 / US
[2021/35]
Former [2018/28]For all designated states
Auspex Pharmaceuticals, Inc.
1090 Horsham Road
North Wales, PA 19454 / US
Inventor(s)01 / GANT, Thomas G.
c/o Auspex Pharmaceuticals, Inc.
400 Interpace Parkway
Parsippany, New Jersey 07054 / US
02 / SHAHBAZ, Manoucherhr
c/o Auspex Pharmaceuticals, Inc.
400 Interpace Parkway
Parsippany, New Jersey 07054 / US
 [2021/35]
Former [2018/29]01 / GANT, Thomas G.
1090 Horsham Road
North Wales, PA 19454 / US
02 / SHAHBAZ, Manoucherhr
1090 Horsham Road
North Wales, PA 19454 / US
Former [2018/28]01 / GANT, Thomas G.
3333 North Torrey Pines Court
Suite 400
La Jolla, CA 92037 / US
02 / SHAHBAZ, Manoucherhr
1261 Liberty Way Suite C
Visa, CA 92081 / US
Representative(s)D Young & Co LLP
3 Noble Street
London EC2V 7BQ / GB
[N/P]
Former [2018/28]D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Application number, filing date17199778.618.09.2009
[2018/28]
Priority number, dateUS20080097896P18.09.2008         Original published format: US 97896 P
[2018/28]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3345905
Date:11.07.2018
Language:EN
[2018/28]
Type: B1 Patent specification 
No.:EP3345905
Date:01.09.2021
Language:EN
[2021/35]
Search report(s)(Supplementary) European search report - dispatched on:EP06.04.2018
ClassificationIPC:C07D455/08, A61K101/00, A61P25/16, C07B59/00
[2020/17]
CPC:
C07D455/06 (EP,CN,US); A61K31/4745 (EP,US); A61K45/06 (US);
A61P1/16 (EP); A61P21/00 (EP); A61P25/00 (EP);
A61P25/14 (EP); A61P25/16 (EP); A61P25/18 (EP);
A61P43/00 (EP); C07B59/00 (CN); C07B59/002 (EP,US);
C07B2200/05 (CN,US) (-)
Former IPC [2018/28]C07D455/08, A61K101/00, A61P25/16
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2019/09]
Former [2018/28]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
TitleGerman:DEUTERIERTE BENZOCHINOLIZINDERIVATE ALS INHIBITOREN DES VESIKULÄREN MONOAMINTRANSPORTERS 2[2018/28]
English:DEUTERATED BENZOQUINOLIZINE DERIVATIVES AS INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2[2018/28]
French:DÉRIVÉS DEUTÉRÉS DE BENZOQUINOLIZINE EN TANT QU'INHIBITEURS DU TRANSPORTEUR DE MONOAMINE VÉSICULAIRE 2[2018/28]
Examination procedure11.01.2019Amendment by applicant (claims and/or description)
11.01.2019Examination requested  [2019/09]
11.01.2019Date on which the examining division has become responsible
03.05.2019Despatch of a communication from the examining division (Time limit: M04)
15.10.2019Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
17.12.2019Reply to a communication from the examining division
03.04.2020Communication of intention to grant the patent
12.08.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
28.09.2020Communication of intention to grant the patent
05.02.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
16.03.2021Communication of intention to grant the patent
20.07.2021Fee for grant paid
20.07.2021Fee for publishing/printing paid
20.07.2021Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP09820972.9  / EP2326643
EP13160950.5  / EP2610254
EP15185548.3  / EP3061760
Opposition(s)02.06.2022No opposition filed within time limit [2022/32]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
17.12.2019Request for further processing filed
17.12.2019Full payment received (date of receipt of payment)
Request granted
08.01.2020Decision despatched
Fees paidRenewal fee
02.12.2017Renewal fee patent year 03
02.12.2017Renewal fee patent year 04
02.12.2017Renewal fee patent year 05
02.12.2017Renewal fee patent year 06
02.12.2017Renewal fee patent year 07
02.12.2017Renewal fee patent year 08
02.12.2017Renewal fee patent year 09
25.09.2018Renewal fee patent year 10
24.09.2019Renewal fee patent year 11
24.09.2020Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.09.2009
AT01.09.2021
CY01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
MK01.09.2021
MT01.09.2021
PL01.09.2021
RO01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
TR01.09.2021
IE18.09.2021
LU18.09.2021
BE30.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
[2024/41]
Former [2024/29]HU18.09.2009
AT01.09.2021
CY01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
MK01.09.2021
PL01.09.2021
RO01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
TR01.09.2021
IE18.09.2021
LU18.09.2021
BE30.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2024/22]HU18.09.2009
AT01.09.2021
CY01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
MK01.09.2021
PL01.09.2021
RO01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
IE18.09.2021
LU18.09.2021
BE30.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2023/29]HU18.09.2009
AT01.09.2021
CY01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
PL01.09.2021
RO01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
IE18.09.2021
LU18.09.2021
BE30.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2023/24]AT01.09.2021
CY01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
PL01.09.2021
RO01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
IE18.09.2021
LU18.09.2021
BE30.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/36]AT01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
PL01.09.2021
RO01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
IE18.09.2021
LU18.09.2021
BE30.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/35]AT01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
PL01.09.2021
RO01.09.2021
SE01.09.2021
SK01.09.2021
SM01.09.2021
IE18.09.2021
LU18.09.2021
BE30.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/34]AT01.09.2021
CZ01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
PL01.09.2021
RO01.09.2021
SE01.09.2021
SK01.09.2021
SM01.09.2021
LU18.09.2021
BE30.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/33]AT01.09.2021
CZ01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
PL01.09.2021
RO01.09.2021
SE01.09.2021
SK01.09.2021
SM01.09.2021
BE30.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/25]AT01.09.2021
CZ01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
PL01.09.2021
RO01.09.2021
SE01.09.2021
SK01.09.2021
SM01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/24]AT01.09.2021
CZ01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
PL01.09.2021
RO01.09.2021
SE01.09.2021
SK01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/21]AT01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
PL01.09.2021
SE01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
Former [2022/12]FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
PL01.09.2021
SE01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
Former [2022/08]FI01.09.2021
LT01.09.2021
SE01.09.2021
BG01.12.2021
NO01.12.2021
Former [2022/07]LT01.09.2021
NO01.12.2021
Documents cited:Search[A]  - FOSTER A B, "Deuterium isotope effects in the metabolism of drugs and xenobiotics: implications for drug design", ADVANCES IN DRUG RESEARCH, ACADEMIC PRESS, LONDON, GB, (19850101), vol. 14, ISSN 0065-2490, pages 1 - 40, XP009086953 [A] 1-14 * paragraph [02.1] - paragraph [02.2] *
 [A]  - SCHWATZ D E ET AL, "Metabolic studies of tetrabenazine, a psychotropic drug in animals and man", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, (19660101), vol. 15, no. 5, ISSN 0006-2952, pages 645 - 655, XP002659733 [A] 1-14 * page 650 *
 [A]  - PALEACU D ET AL, "Tetrabenazine Treatment in Movement Disorders", CLINICAL NEUROPHARMACOLOGY, RAVEN PRESS, NEW YORK, NY, US, (20040901), vol. 27, no. 5, ISSN 0362-5664, pages 230 - 233, XP008144456 [A] 1-14 * abstract *
 [A]  - FISHER MICHAEL B ET AL, "The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOP, CURRENT DRUGS, LONDON, GB, (20060101), vol. 9, no. 1, ISSN 1367-6733, pages 101 - 109, XP009130718 [A] 1-14 * abstract *
by applicantUS2830993
 US3045021
 WO2007130365
 WO2008058261
    - SAVANI et al., Neurology, (20070000), vol. 68, no. 10, page 797
    - KENNEY et al., Expert Review of Neurotherapeutics, (20060000), vol. 6, no. 1, pages 7 - 17
    - ZHANG et al., AAPS Journal, (20060000), vol. 8, no. 4, pages E682 - E692
    - SCHWARTZ et al., Biochem. Pharmacol., (19660000), vol. 15, pages 645 - 655
    - HARPER, Progress in Drug Research, (19620000), vol. 4, pages 221 - 294
    - WANG et al., Curro Pharm. Design, (19990000), vol. 5, pages 265 - 287
    - PAULETTI et al., Adv. Drug. Delivery Rev., (19970000), vol. 27, pages 235 - 256
    - MIZEN et al., Pharm. Biotech., (19980000), vol. I1, pages 345 - 365
    - GAIGNAULT et al., Pract. Med. Chem., (19960000), pages 671 - 696
    - ASGHARNEJAD et al., Transport Processes in Pharmaceutical Systems, Marcell Dekker, (20000000), pages 185 - 218
    - BALANT et al., Eur. J. Drug Metab. Pharmacokinet, (19900000), vol. I5, pages 143 - 153
    - BALIMANE; SINKO, Adv. Drug Delivery Rev., (19990000), vol. 39, pages 183 - 209
    - BROWNE, Clin. Neuropharmacol., (19970000), vol. 20, pages 1 - 12
    - BUNDGAARD, Arch. Pharm. Chem., (19790000), vol. 86, pages 1 - 39
    - BUNDGAARD, Controlled Drug Delivery, (19870000), vol. 17, pages 179 - 196
    - BUNDGAARD, Adv. Drug Delivery Rev., (19920000), vol. 8, pages 1 - 38
    - FLEISHER et al., Adv. Drug Delivery Rev., (19960000), vol. 19, pages 115 - 130
    - FLEISHER et al., Methods Enzymol., (19850000), vol. 112, pages 360 - 381
    - FARQUHAR et al., J. Pharm. Sci., (19830000), vol. 72, pages 324 - 325
    - FREEMAN et al., J. Chem. Soc., Chem. Commun., (19910000), pages 875 - 877
    - FRIIS; BUNDGAARD, Eur. J. Pharm. Sci., (19960000), vol. 4, pages 49 - 59
    - GANGWAR et al., Des. Biopharm. Prop. Prodrugs Analogs, (19770000), pages 409 - 421
    - NATHWANI; WOOD, Drugs, (19930000), vol. 45, pages 866 - 894
    - SINHABABU; THAKKER, Adv. Drug Delivery Rev., (19960000), vol. 19, pages 241 - 273
    - STELLA et al., Drugs, (19850000), vol. 29, pages 455 - 473
    - TAN et al., Adv. Drug Delivery Rev., (19990000), vol. 39, pages 117 - 151
    - TAYLOR, Adv. Drug Delivery Rev., (19960000), vol. 19, pages 131 - 148
    - VALENTINO; BORCHARDT, Drug Discovety Today, (19970000), vol. 2, pages 148 - 155
    - WIEBE; KNAUS, Adv. Drug Delivery Rev., (19990000), vol. 39, pages 63 - 80
    - WALLER et al., Br. J. Clin. Pharmac., (19890000), vol. 28, pages 497 - 507
    - BERGE et al., J. Pharm. Sci., (19770000), vol. 66, pages 1 - 19
    - Remington: The Science and Practice of Pharmacy, supra; Modified-Release Drug Deliver Technology, Marcel Dekker, Inc., (20020000), vol. 126
    - LI et al., Rapid Communications in Mass Spectrometry, (20050000), vol. 19, pages 1943 - 1950
    - JINDAL et al., Journal of Chromatography, Biomedical Applications, (19890000), vol. 493, no. 2, pages 392 - 397
    - SCHWARTZ et al., Biochemical Pharmacology, (19660000), vol. 15, no. 5, pages 645 - 655
    - MEHVAR et al., Drug Metabolism and Disposition, (19870000), vol. 15, no. 2, pages 250 - 255
    - ROBERTS et al., Journal of Chromatography, Biomedical Applications, (19810000), vol. 226, no. 1, pages 175 - 182
    - KO et al., British Journal of Clinical Pharmacology, (20000000), vol. 49, pages 343 - 351
    - WEYLER et al., J. Biol Chem., (19850000), vol. 260, pages 13199 - 13207
    - UEBELHACK et al., Pharmacopsychiatry, (19980000), vol. 31, pages 187 - 192
    - DASILVA et al., Appl. Radiat. hot., (19930000), vol. 44, no. 4, pages 673 - 676
    - POPP et al., J. Pharm. Sci., (19780000), vol. 67, no. 6, pages 871 - 873
    - IVANOV et al., Heterocycles, (20010000), vol. 55, no. 8, pages 1569 - 1572
    - WEYLER et al., Journal of Biological Chemistry, (19850000), vol. 260, pages 13199 - 13207
    - UEBELHACK et al., Pharmacopsychiatry, (19980000), vol. 31, no. 5, pages 187 - 192
    - SCHERMAN et al., Journal of Neurochemistry, (19880000), vol. 50, no. 4, pages 1131 - 1136
    - KILBOUM et al., Synapse, (20020000), vol. 43, no. 3, pages 188 - 194
    - KILBOUM et al., European Journal of Pharmacology, (19970000), vol. 331, no. 2-3, pages 161 - 168
    - ERICKSON et al., Journal of Molecular Neuroscience, (19950000), vol. 6, no. 4, pages 277 - 287
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.